CSIMarket
 
Crispr Therapeutics Ag  (NASDAQ: CRSP)
Other Ticker:  
 
 
Price: $43.4900 $0.19 0.439%
Day's High: $44.14 Week Perf: 9.52 %
Day's Low: $ 42.20 30 Day Perf: 13.37 %
Volume (M): 2,049 52 Wk High: $ 91.10
Volume (M$): $ 89,128 52 Wk Avg: $53.74
Open: $43.70 52 Wk Low: $36.52



 Market Capitalization (Millions $) 3,670
 Shares Outstanding (Millions) 84
 Employees 400
 Revenues (TTM) (Millions $) 37
 Net Income (TTM) (Millions $) -366
 Cash Flow (TTM) (Millions $) -91
 Capital Exp. (TTM) (Millions $) 2

Crispr Therapeutics Ag
CRISPR Therapeutics AG is a biotechnology company that focuses on developing novel therapies using CRISPR gene-editing technology. CRISPR, which stands for Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows precise modifications of genetic material.

The company aims to develop transformative gene-based medicines for serious diseases by utilizing the power of CRISPR. It has a diversified pipeline of potential gene therapies that target a range of genetic disorders, including blood disorders, oncology, regenerative medicine, and rare diseases.

CRISPR Therapeutics AG collaborates with leading academic institutions and pharmaceutical companies to advance its research and development efforts. The company has also established strategic partnerships to support the commercialization and global distribution of its potential therapies.

The company's scientific expertise and cutting-edge technology have garnered significant attention in the biotechnology industry and have the potential to revolutionize the treatment of genetic diseases. As a pioneer in the field of CRISPR gene editing, CRISPR Therapeutics AG continues to push the boundaries of modern medicine and holds great promise for improving patient outcomes.


   Company Address: Baarerstrasse 14 Zug 6300
   Company Phone Number: 561 32 77   Stock Exchange / Ticker: NASDAQ CRSP


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
PLUR        0.67% 
REPL        2.51% 
TWST   -3.16%    
• View Complete Report
   



Management Announcement

CRISPR Therapeutics: A Gene Editing Pioneer Struggles Amidst Milestones

Published Mon, Jan 13 2025 12:01 PM UTC

Overview of Recent DevelopmentsCRISPR Therapeutics, a trailblazer in the realm of gene editing technologies, has recently made noteworthy progress in the treatment of severe genetic disorders, specifically sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The recent approval of its innovative therapy, CASGEVY (exagamglogene autotemcel), alongside th...

Clinical Study

CRISPR Therapeutics Makes Groundbreaking Advances in Gene Therapy for Sickle Cell Disease and Beta-Thalassemia at A...

Published Mon, Dec 9 2024 5:00 PM UTC

CRISPR Therapeutics, a leading biopharmaceutical company at the forefront of gene editing technology, has made significant strides recently in the treatment of serious genetic disorders such as sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). With the recent presentation of preliminary data at the 2024 American Society of Hematology (ASH) Annual Me...

Clinical Study

Unleashing the Power of CRISPR: Innovations in Glaucoma Treatment and a Vision for the Future

Published Wed, May 8 2024 11:01 AM UTC

Gene editing technologies like CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) have revolutionized the field of medicine by offering potential cures for previously incurable diseases. CRISPR Therapeutics, a leading biopharmaceutical company, has made significant strides in utilizing CRISPR-based therapies for the treatment of serious diseases. In this arti...

Shares

Strategic Investment by EcoR1 Capital and SR One Propels Crispr Therapeutics Ag to New Heights

Published Tue, Feb 13 2024 1:30 PM UTC


In a game-changing move for Crispr Therapeutics Ag, new investor EcoR1 Capital and SR One have led a significant round of funding with participation from existing and new investors. This strategic investment is set to have a profound impact on shareholders, as well as the future growth and success of the company.
With 79.414098 million shares outstanding and a curre...

Clinical Study

A New Era in Genetic Medicine: European Commission Approves Groundbreaking CRISPR/Cas9 Therapy for Sickle Cell Disease and Beta Thalassemia, as CRISPR Therapeutics Ventures into Immuno-Oncology and Autoimmune Disease

Published Tue, Feb 13 2024 7:30 AM UTC

For the first time, a revolutionary gene-editing therapy called CASGEVY (exagamglogene autotemcel) has been authorized by the European Commission for the treatment of both Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT). This landmark decision offers hope to over 8,000 patients aged 12 years and older suffering from severe forms of these debilitati...







Crispr Therapeutics Ag's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com